Zobrazeno 1 - 10
of 42
pro vyhledávání: '"John L. Werth"'
Autor:
Joseph Fowler, Jeffrey Sugarman, Lawrence Sher, Chuanbo Zang, John L. Werth, Daniela E. Myers, Daniela Graham, Alexander Agyei Marfo, Liza Takiya
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 951-960 (2023)
Plain Language Summary Atopic dermatitis (AD), also known as eczema, is a chronic skin disease that causes red or flaky skin patches that can become infected and itch. Children with AD often experience sleep disturbance, including difficulty falling
Externí odkaz:
https://doaj.org/article/9f3154ed08464b0a9bf4d464568f6ef9
Publikováno v:
Neurobiology of Disease, Vol 3, Iss 4, Pp 287-298 (1997)
Mitochondrial encephalomyopathies arise from mutations in the mitochondrial or nuclear genome and result in defective energy metabolism. Investigation of cellular pathophysiology in these disorders has been limited to nonneuronal explant cultures suc
Externí odkaz:
https://doaj.org/article/9afc2cd7448b499b977e4c8c1f791586
Autor:
Michael J. Cork, Michael A. O'Connell, Chuanbo Zang, Wendy C Cantrell, Liza Takiya, Michael S. Blaiss, Peter A. Lio, John L. Werth, Jonathan M. Spergel, Aharon Kessel
Publikováno v:
Allergy Asthma Proc
Background: Crisaborole is a nonsteroidal anti-inflammatory phosphodiesterase 4 inhibitor that is approved for the treatment of patients with mild-to-moderate atopic dermatitis (AD); however, the efficacy and safety of crisaborole in patients with AD
Autor:
Paul Sanders, Mark Lebwohl, Bob Geng, Chuanbo Zang, Lauren Miller, Adelaide A. Hebert, John L. Werth, Liza Takiya
Publikováno v:
Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring long-term treatment. Crisaborole significantly improved global AD signs and symptoms in 28-day phase 3 studies of patients aged ≥ 2 years with mild-to-modera
Autor:
John C Su, Liza Takiya, Richard G. Gower, Amy Cha, Joel Schlessinger, John L. Werth, Vivek S. Purohit, William C. Ports, Chuanbo Zang, Bonnie Vlahos, Charles Lynde, Julie S. Shepard, Care Investigators
Publikováno v:
American Journal of Clinical Dermatology
Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD).The aim of this study was to evaluate the safety, effectiveness, and pharmacokinetics (PK) of crisaborole in infant
Autor:
Yeriel Estrada, Etienne Saint-Cyr Proulx, Ana B. Pavel, William C. Ports, John L. Werth, Aisleen Diaz, Ivana Vranic, Bonnie Vlahos, Vivek S. Purohit, Robert Bissonnette, Chuanbo Zang, Emma Guttman-Yassky, Michael A. Zielinski
Publikováno v:
Journal of Allergy and Clinical Immunology. 144:1274-1289
Background Crisaborole ointment 2% is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). The mechanism of action of crisaborole and its effects on lesional measures of disease severity are not y
Autor:
Julie S. Shepard, John C Su, Charles Lynde, Bonnie Vlahos, Chuanbo Zang, Richard G. Gower, Joel Schlessinger, John L. Werth, Liza Takiya, Daniela Graham, Amy Cha
Publikováno v:
Section on Advances in Therapeutics and Technology Program.
PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders
Background: PF-06649751 is a novel, oral, non-catechol-based, D1/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson’s disease. Methods: A 15-week, phase II, double-blind, placebo-c
Autor:
Lawrence F. Eichenfield, Linda Stein Gold, John C Su, Bonnie Vlahos, Chuanbo Zang, Liza Takiya, Amy Cha, John L. Werth, Daniela Graham, Lynda Spelman
Publikováno v:
Pediatrics. 147:302-303
Autor:
Jonathan M. Spergel, Wendy Cantrell, Michael S. Blaiss, Michael O'Connell, Aharon Kessel, Peter A. Lio, Chuanbo Zang, Michael J. Cork, Liza Takiya, John L. Werth
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB97